MRSN Stock Overview
A clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Mersana Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.32 |
| 52 Week High | US$3.63 |
| 52 Week Low | US$0.26 |
| Beta | 1.3 |
| 1 Month Change | 4.59% |
| 3 Month Change | -55.87% |
| 1 Year Change | -91.01% |
| 3 Year Change | -90.28% |
| 5 Year Change | -96.89% |
| Change since IPO | -97.74% |
Recent News & Updates
Emi-Le Trials And TNBC Focus Will Deliver Promise With Risk
Apr 09 Emi-Le's promising clinical trial results and focus on unmet needs in breast cancer could drive significant future revenue and market share gains.Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Mar 27
Recent updates
Emi-Le Trials And TNBC Focus Will Deliver Promise With Risk
Apr 09 Emi-Le's promising clinical trial results and focus on unmet needs in breast cancer could drive significant future revenue and market share gains.Mersana Therapeutics, Inc. (NASDAQ:MRSN) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Mar 27Industry Analysts Just Made A Meaningful Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts
Mar 08Mersana Therapeutics, Inc. (NASDAQ:MRSN) Not Doing Enough For Some Investors As Its Shares Slump 69%
Jan 15Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable
Dec 19Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Dec 01Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly?
Nov 08Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 03Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade
Aug 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%
Aug 13Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues
Jun 19Mersana Therapeutics: On Hold While Waiting For Any Positive News
May 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29Shareholder Returns
| MRSN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -14.2% | -6.3% | 0.8% |
| 1Y | -91.0% | -14.1% | 7.2% |
Return vs Industry: MRSN underperformed the US Biotechs industry which returned -7.6% over the past year.
Return vs Market: MRSN underperformed the US Market which returned 8.2% over the past year.
Price Volatility
| MRSN volatility | |
|---|---|
| MRSN Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: MRSN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MRSN's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 102 | Marty Huber | www.mersana.com |
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175.
Mersana Therapeutics, Inc. Fundamentals Summary
| MRSN fundamental statistics | |
|---|---|
| Market cap | US$45.49m |
| Earnings (TTM) | -US$69.19m |
| Revenue (TTM) | US$40.50m |
1.0x
P/S Ratio-0.6x
P/E RatioIs MRSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRSN income statement (TTM) | |
|---|---|
| Revenue | US$40.50m |
| Cost of Revenue | US$73.02m |
| Gross Profit | -US$32.52m |
| Other Expenses | US$36.67m |
| Earnings | -US$69.19m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 15, 2025
| Earnings per share (EPS) | -0.56 |
| Gross Margin | -80.31% |
| Net Profit Margin | -170.86% |
| Debt/Equity Ratio | -246.6% |
How did MRSN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 11:13 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mersana Therapeutics, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Justin Zelin | BTIG |
| Thomas Shrader | BTIG |